Epilepsy is a neurological condition characterized by recurring seizures. It is caused by abnormal electrical activity in the brain and affects people of all ages, although it most commonly begins in childhood. Seizures are sudden, uncontrolled electrical disturbances in the brain. They can cause a variety of symptoms, including jerking movements of the body, alteration of sensation, and loss of consciousness. The severity of seizures can vary and may last minutes up to a few hours. There are two main types of seizures, focal and generalized. Focal seizures originate in one area of the brain while generalized seizures affect both sides. The type and severity of seizure depends on where the electrical disturbance occurs and how severe it is. In some cases, a person may experience a combination of seizure types. This is called a mixed seizure disorder. Treatment for seizures typically includes medication and lifestyle changes. Anticonvulsants are medicines that reduce the frequency of seizures. Commonly prescribed anticonvulsants include valproic acid, phenytoin, and carbamazepine. Other medications may be used if seizures cannot be adequately controlled with anticonvulsants. Lifestyle modifications can also help prevent and manage seizures. Some general live modifications that can help include avoiding drug and alcohol use, avoiding fatigue, eating a healthy diet, and taking regular exercise. For individuals with epilepsy, getting plenty of sleep is especially important, as seizures are more likely to occur when a person is sleep deprived. Epilepsy is a complex brain disorder that can be life-altering. With careful medical management and lifestyle modifications, people living with epilepsy can often continue to lead normal lives.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States